Compare Danaher Corporation (DHR) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Kimberly Clark Corp — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Kimberly Clark Corp trades at $106.88 (market cap $35.46B). The key difference: Danaher Corporation is far larger — about 4× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.79%). Which is the better fit depends on your goals.
| DHR | KMB | |
|---|---|---|
Market Cap | $140.88B | $35.46B |
Sector | Health | Consumer Staples |
52-Week High | $242.05 | $136.77 |
52-Week Low | $161.91 | $93.05 |
Enterprise Value | $153.66B | $42.00B |
Dividend Yield | 0.8% | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Kimberly-Clark (KMB) trades at $110.18, down 1.98% on the day, with strong technical support at $108 and resistance at $114. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.97 versus $1.93, maintaining a consistent earnings beat streak. Recent business developments include the Arbex joint venture launch and pending Kenvue acquisition, positioning for strategic growth in the consumer goods sector.
KMB offers stable dividend income with a 4.5% yield and strong profitability metrics (12.8% net margin, 146.29% ROE), though elevated P/E (21.31) and P/B (20.36) ratios suggest premium valuation. Risks include consumer sentiment pressures and input cost inflation, but analyst consensus targets $112.33 with 32% buy ratings supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
